Zobrazeno 1 - 10
of 63
pro vyhledávání: ''
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
Myocardial metastasis of nasopharyngeal carcinoma (NPC) is rarely reported in the literature. Some autopsy studies found metastases in more than 10% of cases with malignant neoplasm. However, patients are often diagnosed during the postmortem because
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
Pancreatic cancer (PC) is a highly fatal and aggressive disease with its incidence and mortality quite discouraging. It is of great significance to construct an effective prognostic signature of PC and find the novel biomarker for the optimization of
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Frontiers in Endocrinology
Frontiers in Endocrinology
BackgroundThere are no definite recommendations on the optimal time of initiating radioactive iodine (RAI) therapy for differentiated thyroid cancer (DTC) patients in current relevant guidelines. This study aimed to investigate the relationship betwe
Autor:
Jowita Halupczok-Żyła, Jacek Daroszewski, Łukasz Mizera, Diana Jędrzejuk, Agnieszka Zembska, Katarzyna Kolackov, Marek Bolanowski, Jedrzej Grzegrzolka
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Frontiers in Endocrinology
Frontiers in Endocrinology
IntroductionThe muscle is an endocrine organ controlling metabolic homeostasis. Irisin and myostatin are key myokines mediating this process. Acromegaly is a chronic disease with a wide spectrum of complications, including metabolic disturbances.Purp
Autor:
Yanghui Ye, Song Zheng
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
BackgroundPancreatic cancer has a poor prognosis, and it is traditionally treated with chemotherapy. Fortunately, immunotherapy has rapidly changed the landscape of solid tumor treatment, and improving the survival of cancer patients. However, pancre
Autor:
Zhengang Hu, Hao Zhang, Fan Fan, Zeyu Wang, Jiahao Xu, Yunying Huang, Ziyu Dai, Hui Cao, Xun Zhang, Zhixiong Liu, Quan Cheng
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
DNA methylation patterns are essential in understanding carcinogenesis. However, the relationship between DNA methylation and the immune process has not been clearly established—this study aimed at elucidating the interaction between glioma and DNA
Autor:
Qingpeng Zeng, Yuejun Luo, Guochao Zhang, Peng Wu, Zhihui Zhang, Nan Sun, Zhaoyang Yang, Jie He, Lide Wang, Chaoqi Zhang
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Tumor necrosis factor (TNF) family members participate in the body’s antitumor immunity response and influence tumor prognosis and treatment response. However, little is known about the roles of TNF family members in small cell lung cancer (SCLC).
Autor:
Ran Zeng, Fang Liu, Chen Fang, Jin Yang, Lifeng Luo, Ping Yue, Beili Gao, Yuchao Dong, Yi Xiang
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
ObjectivesThe objective of this study is to evaluate whether PIV (Pan-Immune-Inflammation Value) and PILE [a score derived from PIV, lactate dehydrogenase (LDH), and Eastern Cooperative Oncology Group Performance Status (ECOG PS)] can predict clinica
Publikováno v:
Frontiers in Endocrinology, Vol 12 (2021)
Frontiers in Endocrinology
Frontiers in Endocrinology
BackgroundPapillary thyroid cancer (PTC) in clinically lymph node-negative (cN0) patients is prone toward lymph node metastasis. As a risk factor for tumor persistence and local recurrence, lateral lymph node metastasis (LLNM) is related to the numbe
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology
Frontiers in Immunology
Ovarian cancer (OC) is one of the most malignant tumors whose mortality rate ranks first in gynecological tumors. Although immunotherapy sheds new light on clinical treatments, the low response still restricts its clinical use because of the unique c